Back to results
US 12,600,756 B2Granted
Recombinant modified fibroblast growth factors and therapeutic uses thereof
AssigneeTrefoil Therapeutics, Inc.
InventorsDavid Eveleth, Jennifer Jenkins-Eveleth, Amuthakannan Subramaniam, Ralph Bradshaw
Life of this patent
Estimating the term…
Abstract
Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration of FGFs.
Claims19
A method of treating a corneal injury in a patient, the method comprising administering to the patient a recombinant modified FGF-1 polypeptide comprising an amino acid sequence that has at least 90% sequence identity to SEQ ID NO:
- 206 while retaining Ser at amino acid position 16, Cys at amino acid position 66, and Val at amino acid position 117, and having an N-terminal methionine residue positioned upstream to the first residue of SEQ ID NO:
- 206, wherein the corneal injury is induced by exposure to a vesicant as a gas or vapor, and the first dose is administered within 48 hours of exposure to the vesicant, thereby reducing corneal epithelial cell and/or corneal endothelial cell injury.
Dependencies are inferred from the claim text.